Russia's first domestically developed quadrivalent meningococcal vaccine gains registration amid rising disease concerns

Petrovax Pharm’s new vaccine, Mentera, offers a locally produced option targeting four meningococcal serogroups, potentially strengthening Russia’s immunisation efforts amid increasing infection cases and industrial localisation achievements. Russia has registered what Petrovax Pharm says is the country’s first domestically developed…